New York esophageal squamous cell carcinoma 1 peptide–Major Histocompatibility Complex (NY-ESO-1 peptide–MHC complex) (NY-ESO-1–MHC)

The New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide–Major Histocompatibility Complex (MHC) complex is a highly specific target for cancer immunotherapy, particularly in hematological malignancies such as myeloid leukemia and multiple myeloma. NY-ESO-1 is a cancer-testis antigen (CTA) encoded by the CTAG1B gene; it is typically expressed during embryonic development but restricted to the germ cells of the testis and placenta in adults [1][2]. Because these germline tissues do not express MHC Class I molecules, they are not subject to T-cell recognition, making NY-ESO-1 an exceptionally tumor-specific antigen when re-expressed in cancer cells [3]. In malignant cells, the NY-ESO-1 protein is degraded into peptides, such as the immunodominant SLLMWITQC fragment, which are then presented on the cell surface by MHC Class I molecules, most commonly HLA-A*02:01 [4]. This peptide–MHC complex is the target for T-cell receptor (TCR) engineered T-cell therapies, which utilize modified lymphocytes to recognize and eliminate cells displaying the complex [5]. Unlike CAR-T cells that target surface proteins, TCR-T cells can target these intracellularly derived peptides, expanding the range of treatable targets in leukemia [6]. Clinical trials have demonstrated that targeting this complex can induce significant tumor regression, although challenges such as antigen loss and the requirement for specific HLA types remain [7].

Other names

CTAG1B peptide–MHC complexNY-ESO-1/HLA-A2 complexSLLMWITQC–HLA-A*02:01 complexCancer/testis antigen 1B peptide–MHC

Recognition of the specific NY-ESO-1 peptide presented by MHC Class I molecules by engineered T-cell receptors (TCRs), leading to directed cytotoxic T-cell activation and tumor cell lysis.